Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635c4

WALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Company’s Board of Directors or the Compensation Committee thereof, as applicable, approved the grant of non-qualified stock options to purchase an aggregate of 350,000 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on March 30 and April 3, 2023, respectively (the “Grant Date”). The Inducement Grants have been granted outside…